MRI Contrast Enhancement Using Ferritin Genes and Its Application for Evaluating Anticancer Drug Efficacy in Mouse Melanoma Models

Jae Young Kim, Gunwoo Lee, On Seok Lee, Geo Han, Seunghan Ha, Chil Hwan Oh

Research output: Contribution to journalArticle

Abstract

The study aimed to introduce a ferritin gene probe into a mouse melanoma model to facilitate longitudinal in vivo monitoring of malignant melanoma via magnetic resonance imaging (MRI), thus creating a new prognostic tool and pharmacodynamic resource. B16 cells transfected with the human ferritin heavy chain (hFTH) and human ferritin light chain (hFTL) were subcutaneously inoculated into the dorsal areas of C57BL/6J mice for xenograft models. These xenograft models of malignant melanoma were monitored using the 4.7-T MRI system. Axial slices were acquired at the xenograft site, using T2-weighted spin-echo and T2*-weighted gradient-echo sequences. In addition, the efficacy of anticancer drugs was evaluated in the xenograft models. The hFTH- and hFTL-transfected B16 cells had significantly lower signal intensities in T2- and T2*-weighted MRI images than did the control group (w/o ferritin transfection). This was grossly correlated with tumor progression and could be visualized. The oregonin and oregonin + dacarbazine (DTIC) treated groups showed greater survival rates than the control and DTIC-only groups. We have developed an effective MRI contrast enhancement method using a ferritin gene probe. It can be applied reliably to evaluate the efficacy of drugs in preclinical and clinical trials, greatly assisting the development of new chemotherapeutics.

Original languageEnglish
Pages (from-to)1031-1041
Number of pages11
JournalApplied Magnetic Resonance
Volume48
Issue number10
DOIs
Publication statusPublished - 2017 Oct 1

Fingerprint

genes
mice
magnetic resonance
drugs
augmentation
echoes
probes
cells
progressions
resources
tumors
gradients

ASJC Scopus subject areas

  • Atomic and Molecular Physics, and Optics

Cite this

MRI Contrast Enhancement Using Ferritin Genes and Its Application for Evaluating Anticancer Drug Efficacy in Mouse Melanoma Models. / Kim, Jae Young; Lee, Gunwoo; Lee, On Seok; Han, Geo; Ha, Seunghan; Oh, Chil Hwan.

In: Applied Magnetic Resonance, Vol. 48, No. 10, 01.10.2017, p. 1031-1041.

Research output: Contribution to journalArticle

Kim, Jae Young ; Lee, Gunwoo ; Lee, On Seok ; Han, Geo ; Ha, Seunghan ; Oh, Chil Hwan. / MRI Contrast Enhancement Using Ferritin Genes and Its Application for Evaluating Anticancer Drug Efficacy in Mouse Melanoma Models. In: Applied Magnetic Resonance. 2017 ; Vol. 48, No. 10. pp. 1031-1041.
@article{cb4c3ec8a1844e888c4105c2fd78844b,
title = "MRI Contrast Enhancement Using Ferritin Genes and Its Application for Evaluating Anticancer Drug Efficacy in Mouse Melanoma Models",
abstract = "The study aimed to introduce a ferritin gene probe into a mouse melanoma model to facilitate longitudinal in vivo monitoring of malignant melanoma via magnetic resonance imaging (MRI), thus creating a new prognostic tool and pharmacodynamic resource. B16 cells transfected with the human ferritin heavy chain (hFTH) and human ferritin light chain (hFTL) were subcutaneously inoculated into the dorsal areas of C57BL/6J mice for xenograft models. These xenograft models of malignant melanoma were monitored using the 4.7-T MRI system. Axial slices were acquired at the xenograft site, using T2-weighted spin-echo and T2*-weighted gradient-echo sequences. In addition, the efficacy of anticancer drugs was evaluated in the xenograft models. The hFTH- and hFTL-transfected B16 cells had significantly lower signal intensities in T2- and T2*-weighted MRI images than did the control group (w/o ferritin transfection). This was grossly correlated with tumor progression and could be visualized. The oregonin and oregonin + dacarbazine (DTIC) treated groups showed greater survival rates than the control and DTIC-only groups. We have developed an effective MRI contrast enhancement method using a ferritin gene probe. It can be applied reliably to evaluate the efficacy of drugs in preclinical and clinical trials, greatly assisting the development of new chemotherapeutics.",
author = "Kim, {Jae Young} and Gunwoo Lee and Lee, {On Seok} and Geo Han and Seunghan Ha and Oh, {Chil Hwan}",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s00723-017-0926-5",
language = "English",
volume = "48",
pages = "1031--1041",
journal = "Applied Magnetic Resonance",
issn = "0937-9347",
publisher = "Springer Wien",
number = "10",

}

TY - JOUR

T1 - MRI Contrast Enhancement Using Ferritin Genes and Its Application for Evaluating Anticancer Drug Efficacy in Mouse Melanoma Models

AU - Kim, Jae Young

AU - Lee, Gunwoo

AU - Lee, On Seok

AU - Han, Geo

AU - Ha, Seunghan

AU - Oh, Chil Hwan

PY - 2017/10/1

Y1 - 2017/10/1

N2 - The study aimed to introduce a ferritin gene probe into a mouse melanoma model to facilitate longitudinal in vivo monitoring of malignant melanoma via magnetic resonance imaging (MRI), thus creating a new prognostic tool and pharmacodynamic resource. B16 cells transfected with the human ferritin heavy chain (hFTH) and human ferritin light chain (hFTL) were subcutaneously inoculated into the dorsal areas of C57BL/6J mice for xenograft models. These xenograft models of malignant melanoma were monitored using the 4.7-T MRI system. Axial slices were acquired at the xenograft site, using T2-weighted spin-echo and T2*-weighted gradient-echo sequences. In addition, the efficacy of anticancer drugs was evaluated in the xenograft models. The hFTH- and hFTL-transfected B16 cells had significantly lower signal intensities in T2- and T2*-weighted MRI images than did the control group (w/o ferritin transfection). This was grossly correlated with tumor progression and could be visualized. The oregonin and oregonin + dacarbazine (DTIC) treated groups showed greater survival rates than the control and DTIC-only groups. We have developed an effective MRI contrast enhancement method using a ferritin gene probe. It can be applied reliably to evaluate the efficacy of drugs in preclinical and clinical trials, greatly assisting the development of new chemotherapeutics.

AB - The study aimed to introduce a ferritin gene probe into a mouse melanoma model to facilitate longitudinal in vivo monitoring of malignant melanoma via magnetic resonance imaging (MRI), thus creating a new prognostic tool and pharmacodynamic resource. B16 cells transfected with the human ferritin heavy chain (hFTH) and human ferritin light chain (hFTL) were subcutaneously inoculated into the dorsal areas of C57BL/6J mice for xenograft models. These xenograft models of malignant melanoma were monitored using the 4.7-T MRI system. Axial slices were acquired at the xenograft site, using T2-weighted spin-echo and T2*-weighted gradient-echo sequences. In addition, the efficacy of anticancer drugs was evaluated in the xenograft models. The hFTH- and hFTL-transfected B16 cells had significantly lower signal intensities in T2- and T2*-weighted MRI images than did the control group (w/o ferritin transfection). This was grossly correlated with tumor progression and could be visualized. The oregonin and oregonin + dacarbazine (DTIC) treated groups showed greater survival rates than the control and DTIC-only groups. We have developed an effective MRI contrast enhancement method using a ferritin gene probe. It can be applied reliably to evaluate the efficacy of drugs in preclinical and clinical trials, greatly assisting the development of new chemotherapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85027892637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027892637&partnerID=8YFLogxK

U2 - 10.1007/s00723-017-0926-5

DO - 10.1007/s00723-017-0926-5

M3 - Article

VL - 48

SP - 1031

EP - 1041

JO - Applied Magnetic Resonance

JF - Applied Magnetic Resonance

SN - 0937-9347

IS - 10

ER -